Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Odevixibat
Therapeutic Area : Genetic Disease
Study Phase : Approved
Sponsor : Albireo Pharma
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Bylvay (Odevixibat) is theI BAT inhibitor and first drug approved in the U.S. for the treatment of pruritus in patients 3 months of age and older in all types of progressive familial intrahepatic cholestasis (PFIC).
Brand Name : Bylvay
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 20, 2023
Lead Product(s) : Odevixibat
Therapeutic Area : Genetic Disease
Highest Development Status : Approved
Sponsor : Albireo Pharma
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?